Drugs / Jitongning tablets
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06000956 | Sep 2023 → Dec 2026 expected | ankylosing spondylitis | Tasly Pharmaceutical Group Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Jitongning tablets | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06000956 ↗ |
| Route | Oral | “The participants took orally three tablets of Jitongning tablets, twice a day, for 8 consecutive weeks.” NCT06000956 ↗ |